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Infections are the main cause of morbidity and mortality in pediatric hematology and oncology (PHO) and hematopoietic cell transplan-
tation (HCT) settings in children and adults. The analysis of incidence and outcome of bacterial, fungal, and viral infections in Polish PHO/
HCT centers was performed over a period of 72 months (2012–2017). The summary of infections in 5628 patients with newly diagnosed 
malignancy and 971 HCTs is presented in this paper. Additionally, data of 650 pediatric HCTs from 2012 to 2015 were compared with 
the data of 3200 HCTs in adults. The risk of any infection per patient was higher in HCT vs PHO patients (2062/971 vs 7115/5628; 2.1 vs 
1.3; HR=1.7, p<0.0001). The incidence of bacterial infections was 34,2±0,6% in PHO vs 41,5±1,6% in HCT patients, and the outcome was 
better in PHO patients: 97,9±0,2% vs 91,8±1,0%. The incidence of patients with fungal infection was 8,8±0,4% vs 21,2±1,3%, and the 
outcome was better in PHO patients: 95,9±0,7% vs 85,8±2,3%. Incidence of viral infections was 5,0±1,0% in PHO setting, including part 
of previously transplanted patients, and 47,8±2,2% in HCT setting (60,9±2,3% allo-HCT; 5,6±1,3% auto-HCT). In children, the incidence 
was higher for bacterial (36.0% vs 27.6%), fungal (25.3% vs 6.3%), and viral (56.3% vs 29.3% allo-HCT; 6.6% vs 0.8% auto-HCT) infections 
than in adults (p<0.0001), and the outcome was better for bacterial (95.5% vs 91.4%), fungal (88.0% vs 74.9%), and viral (98.6% vs 92.3%) 
infections. In conclusion, the presented large studies have determined the incidence of infectious complications and their outcomes in 
HCT and PHO centers in Poland.
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All rights reserved.
Keywords:
bacterial infections, invasive fungal infections, viral infections, malignant diseases, oncohematology
Acta Haematologica Polonica 50(3) • September 2019 • 167–173 • DOI: 10.2478/ahp-2019-0027
Introduction: nationwide project
Infections are the main cause of morbidity and mortality in patients 
with cancer or undergoing stem cell transplantation [1]. Children 
and adults with hematologic malignancies are especially susceptible 
to bacterial, fungal, and viral infections due to abnormality of the 
basic mediators of immunity. Factors that predispose these patients 
to infection include the following: alterations of the body’s natural 
barriers, presence of central venous catheters, alteration of the innate 
immune system and acquired immunity, as well as intensive oncologic 
and supportive therapy.
The objective of this paper is to review the results of initiative of Polish 
Society of Pediatric Oncology and Hematology and Polish Society 
of Hematology and Blood Transfusion to collect data on bacterial, 
fungal, and viral infections in pediatric hematology, oncology (PHO) 
and hematopoietic stem cell transplant (HCT) units. Over a period 
of 72 months (2012–2017), data of infections in 5628 patients with 
newly diagnosed pediatric malignancy and 971 pediatric HCTs 
performed in participating centers were analyzed. Patients were also 
analyzed in chronological 2-year subgroups. Additionally, data of 650 
HCTs from 2012 to 2015 were compared with the data of 3200 HCTs 
in adults.
Definitions
Classification of infections. Infections during neutropenia were 
classified as follows: (1) microbiologically documented infection 
(MDI) when pathogenic microorganism was recovered; (2) clinically 
documented infection (CDI) with the presence of signs and symptoms 
of inflammation at anatomic sites and non-recovered pathogen; and 
(3) fever of unknown origin (FUO) in case of fever without a localized 
source of infection or identified pathogen [2]. Severe and very severe 
neutropenia were defined by the peripheral blood absolute neutrophil 
count (ANC) below 0.5x109/L and 0.2x109/L, respectively.
Infectious episodes. Following episodes were reported: 
microbiologically documented bacterial infections; proven/probable/
possible IFI; and latent and sporadic viral infections.
Fungal infections. The diagnosis of IFD was made according to 
EORTC/MSG criteria as proven, probable, or possible [3–5]. All HCT 
and PHO patients were screened with galactomannan test mainly 
during neutropenia or on the basis of clinically driven indications.
Viral infections: They were classified as episodic (diagnosed on the 
basis of clinical manifestation and supplemented with appropriate tests) 
or latent (requiring monitoring at the molecular level) [6–8]. Following 
latent viruses were included in the analysis: cytomegalovirus  (CMV); 
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Epstein-Barr virus (EBV); varicella-zoster virus (VZV); human herpes 
virus 6 (HHV6); polyoma BK virus (BKV); and episodic viruses as 
follows: influenza (FLU), CARV (community-acquired respiratory 
virus, parainfluenza (PIF), metapneumovirus (MPV), respiratory 
syncytial virus (RSV)), and adenovirus (ADV). According to European 
Conference on Infections in Leukemia (ECIL) recommendations, 
preemptive approach was introduced for infections with two latent 
viruses: CMV and EBV [7,8]. PCR-based analysis was used for 
diagnosis of viral infections of material derived from blood, urine, 
or cerebrospinal fluid. CARV viruses were detected by PCR from 
respiratory swabs or bronchoalveolar lavage.
Prophylaxis of infections
Commonly accepted standard strategies have been applied for all 
patients undergoing HCT for prophylactic, empirical, and targeted 
anti-infectious therapy with various agents. The same policies of 
preemptive approach and anti-infectious prophylaxis were applied in all 
participating pediatric HCT centers. Empirical, preemptive, or targeted 
anti-infectious therapy was performed with various antibacterial, 
antiviral, and antifungal agents according to the commonly accepted 
strategies [7–13]. Antibacterial antibiotic prophylaxis was used in 
all centers routinely in neutropenia in PHO and all HCT patients 
and included penicillin, cephalosporin, or ciprofloxacin. Antifungal 
prophylaxis was used in all centers routinely in allo-HCT patients 
during neutropenic phase or immunosuppressive therapy and included 
fluconazole or, rarely, other azoles up to 2014, and then posaconazole 
or voriconazole was used in pediatric allo-HCT patients in GVHD 
phase or for secondary prophylaxis, as well as in AML or high-risk 
ALL during conventional chemotherapy in PHO setting. Acyclovir was 
used in prophylaxis of HSV and VZV infection at least until 1-year 
post-transplant. Weekly screening for DNA-emia and preemptive 
treatment were performed for EBV and CMV reactivation, according 
to European ECIL recommendations. Prevention of Pneumocystis 
jiroveci infection included cotrimoxazole after hematopoietic recovery 
until the end of neutropenia, end of immunosuppressive treatment 
and in all patients with acute leukemia during chemotherapy. A 
commercial immunoglobulin preparations were given in case of 
decreased immunoglobulin concentration during the first month after 
HCT and then monthly until B-cell function recovery. Most of the 
patients receiving myeloablative conditioning were commenced on 
gut rest from the first 5 days after HCT and received total parenteral 
nutrition until hematopoietic recovery. Environmental prophylaxis was 
applied in all HCT and PHO centers [14].
Overall incidence of infections in pediatric 
HCT vs PHO settings
A total number of 9177 confirmed infectious episodes were reported. 
The incidence was higher in HCT patients (n=971) than in PHO 
patients (n=5628) for bacterial (41.5% vs 34.2%, HR=1.4, 95% 
CI=1.2–1.6, p<0.0001), proven/probable/possible fungal (21.2% 
vs 8.8%, HR=2.8, 95% CI=2.3–3.3, p<0.0001), proven/probable 
IFI (9.5% vs 3.0%, HR=3.3, 95% CI=2.5–4.3, p<0.0001), and viral 
(47.8% vs 5.0%, HR=22, 95% CI=18.5–26.4, p<0.0001) infections 
[15]. The incidence of viral infections varied largely between allo-
HCT (60.9%; 451/741) and auto-HCT (5.6%; 13/230). The risk of any 
infection per patient was higher in HCT vs PHO patients (2062/971 vs 
7115/5628; 2.1 vs 1.3; HR=1.7, 95% CI=1.5–1.8, p<0.0001) (Fig. 1.). 
Overall results on incidence and outcome of infections during the first 
analyzed period were published previously [16].
Infections in pediatric hematology and 
oncology setting
Acute lymphoblastic leukemia (ALL)
The analysis included 1363 patients, with newly diagnosed ALL 
(2012–2017). The patients received therapy according to the ALL IC-
BFM 2002 and 2009 (Intercontinental Berlin-Frankfurt-Munster Study 
Group) protocols [17].
Bacterial infections. Overall, 1511 episodes of bacterial MDI 
episodes were diagnosed in 726 out of 1363 (53.2%) children during 
chemotherapy. The number of bacterial episodes was 1–28 per 
person. The overall survival of patients who experienced >1 event 
was lower than survival of those who suffered 1, but no statistically 
significant difference. The most common site of bacterial infection 
was bloodstream (n = 518; 71.3%), followed by gastrointestinal tract 
(n = 443; 61%) and urinary tract (n = 245; 33.7%). Overall, 298/518 
(57.5%) Gram-positive and 199/518 (38.4%) Gram-negative isolates 
were recovered from the bloodstream. In all, 20 children (2.75%) died 
due to sepsis, including six patients (2.4%) in the first analyzed time 
period (2012–2013), and six (2.8%) and eight (3.1%) patients in the 
consecutive ones (2014–2015 and 2016–2017, respectively).
Fungal infections. A total number of 406 episodes in 278/1363 
(20.4%) children were reported as having a fungal infection during 
therapy of ALL, including 41 probable, 28 proven, and 337 possible, 
ranging from 1 to 7 per patients. The proven IFD was diagnosed 
in lungs (10 patients), gastrointestinal tract (7 patients), blood 
(7 patients), central nervous system (CNS) (3 patients), and eye 
socket (1 patients). Eight children (2.9%) died due to IFD: three 
proven and five possible IFD. The median time from ALL diagnosis to 
death was 4.4 months (range: 1–16.6).
Viral infections. 251/1363 (18.4%) children experienced a viral 
infection documented by PCR test. In total, 304 episodes of viral 
infections were identified: 1–4 per person. Five patients (2.0%) 
died due to viral infections. Two children (2.9%) died from CMV and 
AH1N1 co-infection, one (0.8%) due to AH1N1, and two (3.2%) due 
to CMV and RSV co-infection. The median time from diagnosis of 
ALL to death was 9.1 months (4.6–10.8).
Acute myeloid leukemia (AML)
In the study of the epidemiology and profile of bacterial infections (BI), 
invasive fungal disease (IFD) and viral infections (VI) in 250 children 
with initial AML (iAML) and 61 with relapsed/refractory (rAML) [18].
Infectious episodes. In 162 patients with primary AML, there were 
504 episodes of BI (3.1 EIC per patient) while 49 episodes of IFD 
in 26 patients (1.9 EIC per patient) and 39 episodes of VI in 29 
patients (1.4 EIC per patient). In 33 patients with rAML, there were 
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78 episodes of BI (2.4 EIC per patient; p=0.2) while 14 episodes of 
IFD in nine patients (1.6 EIC per patient; p=0.8) and seven episodes 
of VI in seven patients (1.0 EIC per patient; p=0.8).
Incidence. In iAML group, overall, 592 episodes of infectious 
complications (EIC) were recorded in 190 (76.0%) patients (3.1 EIC 
per patient). Out of these 592 EIC, 504 (85.1%) were classified as 
bacterial infections (BI), 49 (8.3%) as proven/probable IFD, and 39 
(6.6%) as VI. Similarly, in 41 (67.2%) patients with rAML disease, 
99 EIC were found (2.4 IC per patient), including BI in 78 (78.8%), 
probable IFD in 14 (14.1%), and VI in 7 (7.1%) cases (p=0.5). Gram-
negative strains were predominant, including multidrug-resistant 
strains in half of the cases. Characteristics of IFD and VI were 
comparable for iAML and rAML.
Survival of infectious complications. Overall, in iAML group, 10 out of 
250 (4.0%) patients died due to EIC: IFD contributed to three deaths, 
whereas BSI caused by Enterobacteriaceae and Pseudomonaceae 
to three and two deaths, respectively. Among rAML group, 6 out of 
61 (9.8%; p=0.08) patients died due to IC caused mainly by BSI of 
Enterobacteriaceae. The survival from infection was significantly lower 
in patients with rAML. The cumulative incidence of infection-related 
mortality was 6.1±2.0% for iAML and 12.2±5.0% for rAML (p=0.045).
HD and NHL
Infectious episodes. Among 129 lymphoma patients, there were 
350 EIC, thus 282/350 (80.6%) episodes of BI, 39/350 (11.1%) 
episodes of VI, and 29/350 (8.3%) episodes of IFD. Bacterial EIC 
were predominant in B-NHL patients; 131/282 (46.5%) episodes of 
BI occurred in 56 patients, while in 26 LBL patients 65/282 (23.0%) 
BI episodes were observed, and in 3 ALCL children 11/282 (3.9%) 
episodes, and in 43 HL children 75/282 (26.6%) episodes [19].
Incidence. During the period of analysis in the group of 328 patients 
treated for lymphoma, at least one EIC was diagnosed in 129/328 
(39.3%) children (including 51 girls, 78 boys, with median age 
10.9 years), thus 86/167 (51.5%) NHL and 43/164 (26.2%) HL 
patients (p=0.002). BI were found in 85/167 (50.9%) NHL and in 
43/164 (26.2%) HL children (p=0.003). VI were diagnosed in 20/167 
(12.0%) NHL and 11/164 (6.7%) HL patients (p=0.2). Diagnosis of 
probable/proven IFD was made in 17 children, including 14/167 
(8.4%) NHL and 3/164 (1.8%) HL patients (p=0.2).
Sites of bacterial infections. GI 96/282 (34.0%) and BSI 90/282 
(31.9%) episodes predominated; UTI were diagnosed in 44/282 
(15.6%), SSTI in 20/282 (7.1%), and other sites in 32/282 (11.4%) 
of BI episodes. The most common bacteria found in GI was 
Enterobacteriaceae 45/96 (46.9%) among Gram-negative strains, 
and Clostridiaceae 31/96 (32.3%), among Gram-positive strains.
Survival from infections. The survival was 94.0% for BI, 74.1% for 
IFD, and 100% for VI (p=0.09). For BI, survival was similar for Gram-
positive and Gram-negative strain (p=0.5). The overall survival of 




   
 
Fig. 1. Overall cumulative incidence of infections in pediatric hematology and oncology (PHO) and 
pediatric hematopoietic stem cell transplantation (HCT) settings between 2012 and 2017: (A and B) 






Fig. 1. Overall cumulative incidence of infections in pediatric hematology and oncology (PHO) and pediatric hematopoietic stem cell 
transplantation (HCT) settings between 2012 and 2017: (A and B) inclu ing possible, pr bable, a  proven IFD; (C and D) i cluding 
probable and proven but not possible IFD
170
A c t a  H a e m a t o l o g i c a  P o l o n i c a
Bone tumors
Infectious complications in 70 children with Ewing sarcoma (ES) 
and 56 with osteosarcoma (OSA) showed that the risk of infection 
was 7.1-fold higher in patients with ES vs OSA. Bacterial infections 
occurred in 74.3% patients with ES and in 41.1% with OSA: 33.0% of 
bacterial episodes were diagnosed as bloodstream (BSI), 31.1% as 
gastrointestinal tract, and 30.1% as urinary tract infection. Infection-
related mortality (IRM) from bacterial infection was 6% vs 15% in ES 
vs OSA patients, respectively. Other infections included 7.1% of IFD 
and 6.3% viral ones. All patients who have died from infection had 
BSI and were in neutropenia. Bacterial infection occurring ≥5  months 
since the beginning of chemotherapy was a risk factor for death [20].
Clostridium difficile infections
Clostridium difficile infection is one of the most common causes of 
nosocomial infectious diarrhea in children in PHO and HCT settings. 
Episodes of CDI occurred in 14% PHO patients. The incidence of 
CDI was higher in patients with hematological malignancies in 
comparison to that with solid tumors. Patients with acute myeloblastic 
leukemia had shorter time to episode of CDI than those with acute 
lymphoblastic leukemia. Patients over 5 years and treated for acute 
leukemia had more severe clinical course of disease in PHO group. In 
HSCT group, CDI occurred in 8% patients. The incidence of CDI was 
higher in patients transplanted for acute leukemia. The recurrence 
rate was 14.7% in PHO and 20.7% in HSCT patients. CDI incidence 
was highest in patients with hematological malignancies. Most of the 
patients experienced mild CDI [21].
Fungal infections in PHO patients
Incidence. IFD incidence among all pediatric patients treated for 
malignancy was 9.2%, including possible in 6.5%, probable in 1.6%, 
and proven IFD in 1.1%. Introduction of antifungal prophylaxis from 
2014 to 2015 in selected groups of patients (AML and high-risk ALL) 
did not change significantly the incidence of IFD in this setting: from 
10.2% in first period to 8.3% in the third one (ns). In AML patients, 
the incidence of proven/probable IFD decreased from 19.7% in the 
first period to 10.8% in the second and to 8.4% in last one, while 
possible IFD from 23.5% and 25.7% to 14.8% in respective periods of 
time. In ALL patients, proven/probable IFD ranged from 6.7% to 4.9% 
and 4.8% in respective periods; however, incidence of possible IFD 
increased from 6.3% to 9.8% and 19.1% in respective periods [15, 22].
Outcome. Success rate of treatment of IFD was 95.9% in pediatric 
malignancy patients. With respect to the level of diagnosis of IFD, 
the outcome was 94.3% for proven, 92.4% for probable, and 96.9% 
for possible IFD. The outcome was 96.2% for children with ALL and 
93.4% with AML [15].
Bacterial infections in HCT pediatric patients
A total number of 273 episodes of BI were diagnosed in 113/308 (36.7%) 
HCT (92 allo-, 22 auto-) children with median age 7 years (range: 
0.02–22). Index of bacterial infection (IBI) was calculated as a ratio of 
patients with at least 1 BI to all HCT patients who underwent this type of 
transplant during analyzed period of time. The risk of BI did not depend 
on the underlying disease, but only on HCT donor type and was the 
highest after MMUD-HCT procedure. Among allo-HCT recipients, the 
IBI was 0.4 (MSD-HCT 0.3; MUD-HCT 0.4; MUD-HCT 0.8; p=0.027) 
and in auto-HCT 0.3 per 1 patient. The profile of BI depended on 
the underlying disease and HCT type while it did not depend on the 
occurrence of acute GVHD. The major cause of infections after allo-
HCT for hematological malignancies and bone marrow failures as well 
as after auto-HCT was Enterobacteriaceae, and G-positive bacteria in 
patients with primary immunodeficiencies [23, 24].
Fungal infections in HCT pediatric patients
Incidence. IFD incidence among pediatric HCT patients was 20.6%, 
including possible in 12.0%, probable in 5.3%, and proven IFD in 
3.3%. Introduction of antifungal prophylaxis from 2014 to 2015 
(in patients in early phase after HCT or with GVHD) resulted in 
significant decrease in incidence of IFD in HCT patients from 27.0% 
in 2012–2013 to 11.7% in 2016–2017 (p<0.001). In AML patients, 
the frequency of proven/probable IFD decreased from 19.2% in first 
period to 17.6% in second period and to 1.5% in the third one while 
possible IFD from 25.5% to 21.6% and 17.4% in respective periods. 
In ALL patients, the incidence of proven/probable IFD decreased 
from 17.9% to 12.7% and 1.4% in respective periods while possible 
IFD varied from 13.4% and 15.2% to 11.3% in respective periods 
[15, 22].
Outcome. Overall outcome of IFD was 85.8%. With respect to the 
level of diagnosis of IFD, the outcome was 90.2%, for proven, 76.9% 
for probable, and 88.7% for possible IFD. The outcome was 84.7% 
for children with ALL and 84.8% with AML [15].
Viral infections in HCT pediatric patients
Incidence. The cumulative incidence was 57.9% in allo-HCT and 
4.8% in auto-HCT patients. More than one pathogen was diagnosed 
in 46.0% of allo-HCT patients. Cumulative incidence of viral infections 
was 28.9% for CMV, 23.8% for BKV, 22.7% for EBV, 10.7% for ADV, 
5.0% for RV, 1.9% for FLU, 1.2% for VZV, 1.2% for HHV-6, 0.7% for 
RSV, 0.5% NV, 0.4% for PIF, 0.4% for RHINO, 0.3% for HSV, 0.1% 
for hMPV, 0.1% for PVB19, and 0.1% for HBV.
Survival. Success rates were 100% after FLU, HBV, VZV, HHV6, or 
RV infections, and lower in other types of infections: EBV (90.7%), 
ADV (93.8%), BKV (94.2%), and CMV (94.6%) [15, 25, 26].
Children versus adults: infections are more 
frequent and have better outcome in children
Incidence. Pediatric patients had 2.9-fold higher incidence of 
infectious complications than adults. Infections were diagnosed 
in 60.8% children and 35.0% adults, including 69.1% vs 63.5% in 
allo-HCT, and 33.1% vs 20.8% in auto-HCT patients, respectively. 
Bacterial infections were more frequent in children (36.0% vs 27.6%). 
In adults, G-negative bacteria were more frequent than G-positive 
(64.6% vs 44.8%). The incidence was higher in children also for IFD 
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(25.3% vs 6.3%), and viral infections both after allo-HCT (56.3% vs 
29.3%) and auto-HCT (6.6% vs 0.8%).
Outcome. Pediatric patients had 2.5-fold better survival of infections 
than adults. Children had better survival from bacterial (95.5% vs 
91.4%; p=0.0011), fungal (88.0% vs 74.9%; p<0.001), and viral 
(98.6% vs 92.3%; p=0.0096) infections. Infection-related mortality 
was lower in children (7.8% vs 18.4%; p<0.0001). No child died of 
infection after auto-HCT. In multivariate analysis, the risk factors for 
death from infection were following: adult vs children, diagnosis of 
acute leukemia, mismatched transplants, chronic GVHD, infection 
with Gram-negative bacteria, CMV reactivation, and also duration of 
infection >21 days [27].
Conclusions
Presented large studies have determined the incidence of infectious 
complications and their outcome in pediatric HCT and PHO 
departments, as well as adult HCT centers in Poland. Emerging 
data from Polish PHO and HCT centers indicate high incidence of 
infectious complications in these populations [28–30]. Although 
the rate of bacterial infections is similar to data reported from 
international centers both for children and adults, our data suggest 
that the incidence of IFD in pediatric ALL and AML both in PHO and 
HCT settings is much higher than it was recently anticipated. Viral 
infections occur in a high rate of allo-HCT pediatric and adult patients, 
thus might severely compromise the overall benefit of transplant.
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